Congenital Adrenal Hyperplasia Clinical Trial
Official title:
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of SPR001 (Tildacerfont) in Reducing Supraphysiologic Glucocorticoid Use in Adult Subjects With Classic Congenital Adrenal Hyperplasia
An investigation of the ability of Tildacerfont to reduce supraphysiologic glucocorticoid dosing in classic CAH subjects up to 76 weeks of treatment. Optional open label extension up to 240 weeks.
This is a study that will evaluate the ability of Tildacerfont to reduce the glucocorticoid steroid dose used by adult CAH subjects. The first 24-weeks will be a double-blind, placebo controlled, comparison of Tildacerfont vs Placebo. The following 52-weeks will allow all subjects to move to open label Tildacerfont to continue to reduce steroid dose where appropriate, and observe long term safety. Subjects will be offered a long term open label extension up to 240 weeks. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03687242 -
Study to Evaluate the Safety and Efficacy of SPR001 in Subjects With Classic Congenital Adrenal Hyperplasia
|
Phase 2 | |
Not yet recruiting |
NCT04087148 -
Linear Growth of Children With Congenital Adrenal Hyperplasia
|
||
Completed |
NCT03162159 -
Adult Height Prediction in Congenital Adrenal Hyperplasia
|
||
Recruiting |
NCT05687474 -
Baby Detect : Genomic Newborn Screening
|
||
Enrolling by invitation |
NCT05162950 -
Effects and Importance of Epinephrine/Adrenalin Deficiency in CAH
|
||
Withdrawn |
NCT03532022 -
Open-label Comparison of Chronocort® Versus Standard Glucocorticoid Replacement Therapy
|
Phase 3 | |
Recruiting |
NCT02795871 -
Prenatal Dex Study
|
N/A | |
Completed |
NCT02934399 -
Dynamic Hormone Diagnostics in Endocrine Disease
|
||
Recruiting |
NCT04903587 -
Gonadal Changes In Congenital Adrenal Hyperplasia Patients
|
||
Not yet recruiting |
NCT04536662 -
Comparisons of Different Forms of Glucocorticoid on the Recovery of Reproductive Function in Patients With 21α-hydroxylase Deficiency
|
Phase 4 | |
Recruiting |
NCT04463316 -
GROWing Up With Rare GENEtic Syndromes
|
||
Active, not recruiting |
NCT04490915 -
Global Safety and Efficacy Registration Study of Crinecerfont for Congenital Adrenal Hyperplasia
|
Phase 3 | |
Completed |
NCT01807364 -
Cardiovascular Risk Profile in Patients With Congenital Adrenal Hyperplasia
|
N/A | |
Completed |
NCT02804178 -
A Study of ATR-101 for the Treatment of Congenital Adrenal Hyperplasia
|
Phase 2 | |
Completed |
NCT03019614 -
An Open Label Study in Healthy Volunteers to Compare Chronocort® to Hydrocortisone
|
Phase 1 | |
Not yet recruiting |
NCT04293133 -
Final Height in Patients With CAH
|
||
Recruiting |
NCT03897504 -
Surgical Evaluation of Using the Prepuce in Feminizing Genitoplasty
|
N/A | |
Recruiting |
NCT05663320 -
A Study of a Virtual Education-Based Transition Intervention to Improve Transition Readiness in Adolescent and Young Adults With Congenital Adrenal Hyperplasia
|
N/A | |
Active, not recruiting |
NCT04806451 -
Global Safety and Efficacy Registration Study of Crinecerfont in Pediatric Patients With Classic Congenital Adrenal Hyperplasia (CAHtalyst Pediatric Study)
|
Phase 3 | |
Completed |
NCT01875640 -
Decision Support for Parents Receiving Information About Child's Rare Disease
|